Commonwealth Medicine's newborn screening experts have developed an algorithm that can be used to tell when a newborn's genotype may need to be retested. Learn more about this formula, which can determine when alleleic dropout has occurred, and find out why this practice could be vital for newborn screening programs across the country in this presentation.

In this presentation, Stephanie Tran, PharmD, clinical consultant pharmacist, explains how a retrospective compounding monitoring program demonstrated a reduction in per member per year spend through the placement of select high-cost compounding ingredients on prior authorization.

Director of Child and Family Policy Audrey Smolkin discusses interventions to promote children's resilience to minimize the long-term effects of trauma.

Karen Clements, senior project director, Research and Evaluation, co-authored this poster on providing Medicaid populations with access to advanced hep C treatments which was nominated for best poster at the recent Academy Health 2020 Annual Research Meeting.

For children of color, early-life traumas increase the risk for long-term physical and mental health issues. Audrey Smolkin, director of Child and Family Policy at the UMass Med School, discusses the need for training on the link between race, trauma, and resilience.

Reviewing applications for disability retirement benefits is a complex and time-sensitive process. Getting it right protects plan members and the financial soundness of the plan itself. Commonwealth Medicine empowers its team of licensed and credentialed case reviewers with secure, cloud-based technology to maintain operational continuity—even during a pandemic. The result is accurate, fair and timely disability recommendations.

Pharmacy experts from the University of Massachusetts Medical School and Commonwealth Medicine completed a study on whether the overall benefit of sacubitril/valsartan outweighed the cost of the drug within a Medicaid population. Previous studies have shown that patients treated with sacubitril/valsartan had lower rates of hospitalizations, but before now, the data on the economic impact of the drug on a Medicaid population was limited.

The Director of the Charitable Trusts Unit, within the New Hampshire Attorney General’s office, is charged with reviewing transactions involving health care charitable trusts, including non-profit hospitals, to determine whether these transactions are in the best interest of the community. The Charitable Trusts Unit retained the Health Law & Policy team at Commonwealth Medicine, UMass Medical School, to perform a thorough, impartial review of the Hospital Corporation of America’s (HCA) proposed acquisition of Frisbie Memorial Hospital.  

Discover the comprehensive and customized approach Commonwealth Medicine's Disability Evaluations Team takes toward reviewing the 40,000+ disability evaluations it screens every year.

Find keys to success, policy recommendations, and implementation tools for starting a Recovery Coach program in your community. Commonwealth Medicine’s Health Law & Policy experts Katharine London, MS, and Jeremy Tourish, MPH, share research on the impact Recovery Coaches had in the battle against opioid use disorder in six states.